Trial · NCT02754570
The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
NCT02754570, Not applicable, Completed, University of Colorado, Denver; results first posted 2019-11-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure. Trials, record NCT02754570. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02754570
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
- NCT number
- NCT02754570
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 27 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Glaucoma, Open-angle, Hypertension, Ocular
- Interventions
- Pilocarpine
- First posted
- 2016-04-28
- Last updated
- 2019-11-07
- Results first posted
- 2019-11-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Intraocular Pressure From Baseline at Visit 3 | Two 24-hour visits: Baseline/Visit 2; Up to week 4/Visit 3 | Subjects will be enrolled at the first visit. Patients already on latanoprost may proceed immediately with the second visit. Patients on a different prostaglandin analog medication will be switched to latanoprost for at least 6 weeks. At second visit, intraocular pressure and blood pressure will be measured every 2 hours for a 24-hour period. At any point over the next 4 weeks, another 24-hour visit will be performed. This time, a dose of pilocarpine 2% will be administered at 4 different times in addition to the latanoprost . As before, intraocular pressure and blood pressure will be measured every 2 hours. After visit 3, subjects will return to their prior treatment regimen. Change in the intraocular pressure from the second and the third visit will be determined. 8 diurnal readings and 4 nocturnal readings were averaged separately during both Visit 2 for the PGA Monotherapy and Visit 3 for Pilocarpine+PGA |
| Secondary | Change in Ocular Perfusion Pressure | Two 24-hour visits: Baseline/Visit 2; Up to week 4/Visit 3 | Ocular perfusion pressure will calculated from the intraocular pressure and blood pressure measurements. At Baseline/Visit 2, intraocular pressure and blood pressure will be measured every 2 hours for a 24-hour period. At any point over the next 4 weeks, another 24-hour visit (Visit 3) will be performed. This time, a dose of pilocarpine 2% will be administered at 4 different times in addition to the latanoprost (PGA monotherapy). As before, intraocular pressure and blood pressure will be measured every 2 hours. 8 diurnal readings and 4 nocturnal readings were averaged separately during both Visit 2 for the PGA Monotherapy and Visit 3 for Pilocarpine+PGA |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Intraocular Pressure From Baseline at Visit 3 | Two 24-hour visits: Baseline/Visit 2; Up to week 4/Visit 3 | Patients who are using a prostaglandin analog (PGA) will be monitored at visit two. At visit 3, pilocarpine will be added four times per day to the PGA therapy. | mmHg | MEAN |
| SECONDARY | Change in Ocular Perfusion Pressure | Two 24-hour visits: Baseline/Visit 2; Up to week 4/Visit 3 | Patients who are using a prostaglandin analog (PGA) will be monitored at visit two. At visit 3, pilocarpine will be added four times per day to the PGA therapy. | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Intraocular Pressure From Baseline at Visit 3 | Pilocarpine Group | Visit 2: Nocturnal PGA | 21.1 | Standard Error 0.7 | mmHg |
| Change in Intraocular Pressure From Baseline at Visit 3 | Pilocarpine Group | Visit 2: Diurnal PGA | 18.2 | Standard Error 0.5 | mmHg |
| Change in Intraocular Pressure From Baseline at Visit 3 | Pilocarpine Group | Visit 3: Nocturnal PGA | 20.0 | Standard Error 0.6 | mmHg |
| Change in Intraocular Pressure From Baseline at Visit 3 | Pilocarpine Group | Visit 3: Diurnal PGA | 17.1 | Standard Error 0.4 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 2: Diurnal Ocular Perfusion Pressure | 44.12 | Standard Deviation 1.2 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 2: Nocturnal Ocular Perfusion Pressure | 37.2 | Standard Deviation 1.3 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 2: Diurnal Systolic Blood Pressure | 132.5 | Standard Deviation 2.8 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 2: Nocturnal Systolic Blood Pressure | 125.8 | Standard Deviation 2.9 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 3: Diurnal Ocular Perfusion Pressure | 44.3 | Standard Deviation 1.1 | mmHg |
| Change in Ocular Perfusion Pressure | Pilocarpine Group | Visit 3: Nocturnal Ocular Profusion Pressure | 37.1 | Standard Deviation 1.2 | mmHg |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow5
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pilocarpine Group | 27 | |
| Overall Study | Visits 1 and 2 (PGA Only) | Pilocarpine Group | 27 | |
| Overall Study | Visit 3 (PGA + Pilocarpine) | Pilocarpine Group | 27 | |
| Overall Study | COMPLETED | Pilocarpine Group | 27 | |
| Overall Study | NOT COMPLETED | Pilocarpine Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pilocarpine Group | 0 | 27 |
| Total, all-cause mortality | PGA Monotherapy | 0 | 27 |
| Total, other adverse events | Pilocarpine Group | 0 | 27 |
| Total, other adverse events | PGA Monotherapy | 0 | 27 |
| Total, serious adverse events | Pilocarpine Group | 0 | 27 |
| Total, serious adverse events | PGA Monotherapy | 0 | 27 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001082 | Colorado Clinical and Translational Sciences Institute | SOKOL, RONALD J. | UNIVERSITY OF COLORADO DENVER | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Pilocarpine Group vs PGA Monotherapy: deaths from any cause | Trial comparisons |
| Pilocarpine Group vs PGA Monotherapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02754570
GET https://conductscience.org/api/trials/v1/NCT02754570/registered